Abstract:
Human prion protein, PrP, selectively presents the epitope MDEYSNQNN (SEQ ID No. 14) when PrP misfolds. The misfolded form of human PrP is associated with various disease states. The present invention provides an antibody useful to detect and treat such diseases, including cancer such as ovarian cancer and lymphomas, and transmissible spongiform encephalopathies such as CJD. Also provided is an immunoconjugate in which the antibody is conjugated with urease as cytotoxin.
Abstract translation:当PrP错误折叠时,人朊蛋白PrP选择性地呈现表位MDEYSNQNN(SEQ ID No.14)。 人类PrP的错误形式与各种疾病状态有关。 本发明提供了可用于检测和治疗包括癌症如卵巢癌和淋巴瘤以及传染性海绵状脑病如CJD的疾病的抗体。 还提供了免疫偶联物,其中抗体与脲酶作为细胞毒素缀合。
Abstract:
The disclosure pertains to antibodies that bind A-beta oligomers and methods of making and using said antibodies. Also provided are chimeric or humanized antibodies, including antibodies having CDRs in Table 2 and/or having a sequence as set forth in Table 4B or a sequence with at least 50% sequence identity thereto optionally wherein the CDR amino acid sequences are as set for forth in SEQ ID Nos: 74-79. Also provided are methods and uses thereof as well as kits comprising said antibodies.
Abstract:
The disclosure pertains to antibodies that specifically bind W68 in the context of DAGWGNL (SEQ ID NO: 1). Also provided are isolated peptides, isolated nucleic acids, immunogens, compositions, kits, and methods of using said reganents to detect misfolded TDP-43.
Abstract:
The disclosure pertains to antibodies that bind A-beta oligomers and methods of making and using said antibodies. Also provided are chimeric or humanized antibodies, including antibodies having CDRs in Table 2 and/or having a sequence as set forth in Table 4B or a sequence with at least 50% sequence identity thereto optionally wherein the CDR amino acid sequences are as set for forth in SEQ ID Nos: 74-79. Also provided are methods and uses thereof as well as kits comprising said antibodies.
Abstract:
The disclosure pertains to antibodies that bind A-beta oligomers and methods of using said antibodies. Also provided are chimeric or humanized antibodies, including antibodies having specific CDRs identified herein, or a sequence with at least 80% sequence identity to specific VH sequences identified herein, optionally wherein the CDR H3 amino acid sequence is as set forth in any one of SEQ ID NOs: 31-36, 38-40, or 42-50. Also provided are methods and uses thereof as well as kits comprising said antibodies.
Abstract:
Provided herein are an exogenous antibody that binds selectively to a misfolded form of human FasR, and methods and uses for said antibody. Specifically disclosed is the antibody designated AMF 3a-118 which selectively binds the peptide represented by LHHDGQFCH (SEQ ID NO:2) and the antibody designated AMF 3d-19 which selectively binds the peptide represented by NSTVCEH (SEQ ID NO:5).